{
    "Trade/Device Name(s)": [
        "CRYOcheck Chromogenic Factor IX"
    ],
    "Submitter Information": "Precision BioLogic Inc.",
    "510(k) Number": "K214002",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031829"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGP"
    ],
    "Summary Letter Date": "December 23, 2022",
    "Summary Letter Received Date": "December 21, 2021",
    "Submission Date": "December 20, 2021",
    "Regulation Number(s)": [
        "21 CFR 864.7290"
    ],
    "Regulation Name(s)": [
        "Factor Deficiency Test"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Factor IX"
    ],
    "Specimen Type(s)": [
        "Human plasma",
        "Citrated human plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family",
        "ACL TOP Family 50 Series",
        "IL ACL TOP 700 CTS",
        "IL ACL TOP 700",
        "IL ACL TOP 750 CTS",
        "IL ACL TOP 750",
        "IL ACL TOP 300"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Quantitative chromogenic measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for CRYOcheck Chromogenic Factor IX assay to quantitatively determine factor IX activity in citrated human plasma for identification of factor IX deficiency and aid in management of hemophilia B.",
    "Indications for Use Summary": "For quantitative determination of factor IX activity in 3.2% citrated human plasma to identify factor IX deficiency and aid in management of hemophilia B in individuals aged 2 years and older; for in vitro diagnostic use.",
    "fda_folder": "Hematology"
}